MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-19-2026
Tandem Diabetes Care Cost of Revenue 2011-2026 | TNDM
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Tandem Diabetes Care
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 469 M | 451 M | 380 M | 388 M | 327 M | 238 M | 168 M | 94 M | 63.5 M | 60.7 M | 46.3 M | 34.5 M | 22.8 M | 3.82 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 469 M | 3.82 M | 196 M |
Quarterly Cost of Revenue Tandem Diabetes Care
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 115 M | 115 M | 116 M | - | 119 M | 109 M | 97 M | - | 95.9 M | 94.2 M | 86.5 M | - | 100 M | 98.3 M | 84.8 M | - | 82.9 M | 79.7 M | 67.8 M | - | 58.3 M | 54.8 M | 47.7 M | - | 44 M | 43.4 M | 32.6 M | - | 24.5 M | 19 M | 15.9 M | - | 15.1 M | 13.3 M | 12.2 M | - | 13.9 M | 14.8 M | 13.1 M | - | 10.2 M | 10.9 M | 9.5 M | - | 9.12 M | 6.81 M | 7.2 M | - | 5.24 M | 5.12 M | 3.42 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 119 M | 3.42 M | 50 M |
Cost of Revenue of other stocks in the Medical devices industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aethlon Medical
AEMD
|
3.87 M | $ 2.11 | - | $ 3.29 M |  USA |
 |
AdaptHealth Corp.
AHCO
|
2.64 B | $ 10.42 | - | $ 1.41 B | USA |
 |
Allied Healthcare Products
AHPI
|
24.5 M | - | 3.58 % | $ 2.21 M | USA |
 |
Butterfly Network
BFLY
|
33.2 M | $ 3.91 | - | $ 828 M | USA |
 |
Acutus Medical
AFIB
|
10.3 M | - | -26.83 % | $ 2.62 M | USA |
 |
CONMED Corporation
CNMD
|
624 M | $ 37.41 | - | $ 1.16 B | USA |
 |
Alphatec Holdings
ATEC
|
232 M | $ 12.6 | - | $ 1.89 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
104 M | $ 8.38 | - | $ 602 M |  Israel |
 |
Aziyo Biologics
AZYO
|
5.7 M | - | 1.37 % | $ 20.5 M | USA |
 |
EDAP TMS S.A.
EDAP
|
37.6 M | $ 3.96 | 1.02 % | $ 148 M |  France |
 |
Avinger
AVGR
|
5.65 M | - | -20.74 % | $ 369 K | USA |
 |
BIOLASE
BIOL
|
32.4 M | - | -13.19 % | $ 166 K | USA |
 |
Boston Scientific Corporation
BSX
|
6.22 B | $ 69.79 | - | $ 103 B | USA |
 |
Establishment Labs Holdings
ESTA
|
64.8 M | $ 63.48 | - | $ 1.88 B |  Costa-rica |
 |
Conformis
CFMS
|
38.8 M | - | - | $ 16.4 M | USA |
 |
Apollo Endosurgery
APEN
|
34.4 M | - | - | $ 475 M | USA |
 |
Helius Medical Technologies
HSDT
|
583 K | $ 2.19 | - | $ 1.33 M | USA |
 |
Cytosorbents Corporation
CTSO
|
10.5 M | $ 0.65 | -8.13 % | $ 35.4 M | USA |
 |
Cutera
CUTR
|
171 M | - | -10.19 % | $ 1.99 M | USA |
 |
Dynatronics Corporation
DYNT
|
21.4 M | - | 14.99 % | $ 929 K | USA |
 |
IRIDEX Corporation
IRIX
|
30.1 M | $ 1.33 | - | $ 21.5 M | USA |
 |
ClearPoint Neuro
CLPT
|
12.3 M | $ 11.03 | - | $ 298 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
76 M | - | - | $ 3.31 B | USA |
 |
LivaNova PLC
LIVN
|
448 M | $ 61.43 | - | $ 3.35 B |  Britain |
 |
Neovasc
NVCN
|
556 K | - | - | $ 111 M |  Canada |
 |
InMode Ltd.
INMD
|
79.5 M | $ 13.43 | - | $ 868 M | Israel |
 |
MiMedx Group
MDXG
|
73 M | $ 4.41 | - | $ 652 M | USA |
 |
GBS
GBS
|
1.81 M | - | -0.57 % | $ 7.12 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
21.9 M | $ 2.59 | - | $ 152 M | Israel |
 |
Abbott Laboratories
ABT
|
19.3 B | $ 109.95 | - | $ 191 B | USA |
 |
Delcath Systems
DCTH
|
11.8 M | $ 9.81 | - | $ 351 M | USA |
 |
Bio-Rad Laboratories
BIO
|
1.19 B | $ 261.24 | - | $ 7.37 B | USA |
 |
Insulet Corporation
PODD
|
768 M | $ 224.66 | - | $ 15.8 B | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
728 M | $ 9.01 | - | $ 694 M | USA |
 |
Profound Medical Corp.
PROF
|
3.92 M | $ 5.71 | - | $ 180 M | Canada |
 |
AxoGen
AXGN
|
57.9 M | $ 32.84 | - | $ 1.51 B | USA |
 |
Align Technology
ALGN
|
1.2 B | $ 169.45 | - | $ 12.7 B | USA |
 |
Bruker Corporation
BRKR
|
1.72 B | $ 32.76 | - | $ 4.88 K | USA |
 |
AVITA Medical
RCEL
|
12.8 M | $ 4.62 | 5.0 % | $ 129 M |  Australia |